Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Positive ph 3 data with Iza-Bren (EGFR×HER3 TOPO1-ADC) for pretreated mTNBC in China.
Joins a growing list of effective TOPO1 ADCs for mTNBC – though none tested after prior TOPO1 ADC treatment. 1L IZABRIGHT-B01 trial ongoing to confirm role beyond China.”
Other articles featuring Paolo Tarantino.